Skip to main navigation
Skip to search
Skip to main content
Pure University (For Demo Only) Home
Help & FAQ
English
中文
Home
Profiles
Research units
Research output
Equipment
Datasets
Activities
Prizes
Impacts
Projects
Press/Media
Search by expertise, name or affiliation
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
Darrell White
Engineering
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Carfilzomib
100%
Daratumumab
50%
Effective Treatment
50%
First-line Therapy
50%
Health Technology
50%
Highly Effective
50%
Multiple Myeloma
50%
Myeloma
100%
Novel Therapies
50%
Pomalidomide
100%
Real-world Observational Study
50%
Relapsed or Refractory multiple Myeloma
100%
Sequential Use
100%
Treatment Options
50%
Two-agent
50%
Medicine and Dentistry
Carfilzomib
100%
Daratumumab
50%
Multiple Myeloma
100%
Myeloma
100%
Observational Study
50%
Pomalidomide
100%
Pharmacology, Toxicology and Pharmaceutical Science
Carfilzomib
100%
Daratumumab
50%
Multiple Myeloma
100%
Myeloma
100%
Observational Study
50%
Pomalidomide
100%
Nursing and Health Professions
Carfilzomib
100%
Daratumumab
50%
Multiple Myeloma
100%
Myeloma
100%
Pomalidomide
100%